Samsung Biologics and AstraZeneca have entered a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s biologics therapeutics, which could be increased to $545.6 million.   By leveraging Samsung Biologics’ robust expertise and capabilities in the manufacturing of high-quality biopharmaceuticals, this...